Combination CD200R/PD-1 blockade in a humanised mouse model

There is an increasing number of immune-checkpoint inhibitors being developed and approved for cancer immunotherapy. Most of the new therapies aim to reactivate tumour-infiltrating T cells, which are responsible for tumour killing. However, in many tumours, the most abundant infiltrating immune cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Fellermeyer, Martin, Anzilotti, Consuelo, Paluch, Christopher, Cornall, Richard J, Davis, Simon J, Gileadi, Uzi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112683/
https://www.ncbi.nlm.nih.gov/pubmed/37082107
http://dx.doi.org/10.1093/immadv/ltad006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112683/
https://www.ncbi.nlm.nih.gov/pubmed/37082107
http://dx.doi.org/10.1093/immadv/ltad006

Ejemplares similares